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Naftopidil, an a1-adrenoceptor antagonist, has been shown to inhibit nocturnal polyuria in patients with
lower urinary tract symptom. However, it remains unclear how naftopidil decreases nocturnal urine
production. Here, we investigated the effects of naftopidil on arginine-vasopressin (AVP) plasma level
and urine production and osmolality in rats centrally administered with noradrenaline (NA). NA (3 or
30 mg/kg) was administered into the left ventricle (i.c.v.) of male Wistar rats 3 h after naftopidil pre-
treatment (10 or 30 mg/kg, i.p.). Blood samples were collected from the inferior vena cava 1 h after NA
administration or 4 h after peritoneal administration of naftopidil; plasma levels of AVP were assessed by
ELISA. Voiding behaviors of naftopidil (30 mg/kg, i.p.)-administered male Wistar rats were observed
during separate light- and dark cycles. Administration of NA decreased plasma AVP levels and elevated
urine volume, which were suppressed by systemic pretreatment with naftopidil (30 mg/kg, i.p.). Urine
osmolality decreased 1 h after NA administration. However, naftopidil by itself had no effect on plasma
AVP levels or urodynamic parameters during light- and dark cycles. Our ﬁndings suggest that systemic
administration of naftopidil could prevent central noradrenergic nervous system-mediated decline in
AVP secretion and increase in urine production in rats.
© 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Naftopidil is an a1-adrenoceptor antagonist that used in the
treatment of benign prostatic hyperplasia (BPH)-associated lower
urinary tract symptoms (LUTS) owing to its effects in reducing
resistance in the prostatic urethra (1). In male patients with LUTS,
naftopidil has also been shown to be effective against nocturia (2).
Furthermore, Yokoyama et al. (3) reported that nocturnal polyuria
in male patients with LUTS signiﬁcantly decreased upon naftopidil
administration, indicating that it can directly reduce nocturnal
urine production. Recently, another study found that naftopidil can
cross the bloodebrain barrier to easily enter the central nervous
system (4). However, the mechanism bywhich naftopidil decreases
nocturnal urine production has still not been well understood.328.
rmacological Society.
g by Elsevier B.V. on behalf of Japa
d/4.0/).Arginine vasopressin (AVP), an antidiuretic hormone, is syn-
thesized in the supraoptic and paraventricular nuclei of the hypo-
thalamus and plays an important role in the maintenance of serum
osmolality and volume through free water excretion. The release of
AVP into the plasma, induced by both osmotic and non-osmotic
stimuli, is modulated by brain adrenoceptors (5). In healthy
adults, diurnal secretion of AVP into peripheral blood peaks during
nighttime (6), and is regulated by the circadian rhythm. However,
patients with nocturnal polyuria do not show signiﬁcantly elevated
plasma AVP levels at nighttime, suggesting that abnormal diurnal
variation in AVP secretion is highly prevalent in these patients (7,8).
Spontaneously hypertensive rats (SHRs) are a valuable tool for
exploring the pathogenesis of hypertension-related bladder
dysfunction. These rats exhibit increased voiding frequency and
decreased bladder blood ﬂow compared to the non-hypertensive
Wistar rats (9,10). Saito et al. (11) revealed that naftopidil de-
creases micturition frequency and urine production in SHRs during
the light-cycle. It has been reported that basal and Kþ-stimulated
release of endogenous noradrenaline (NA) from the paraventricular
hypothalamic nucleus was increased in SHRs compared withnese Pharmacological Society. This is an open access article under the CC BY-NC-ND
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activity is enhanced in the central nervous system of SHRs (12).
Furthermore, inhibition of NA synthesis in the posterior hypothal-
amus by 6-hydroxydopamine was demonstrated to lower blood
pressure in SHRs (13).
Based on these reports, we postulated that naftopidil either
directly or indirectly regulates AVP secretion via brain adreno-
ceptors, leading to reduction in urine frequency and production at
night. In the present study, we examined whether naftopidil
modulates plasma AVP levels and urine production in rats centrally
administered with NA.
2. Materials and methods
2.1. Animals
All animal care and experimental procedures complied with the
guiding principles for care and use of laboratory animals approved
by Kochi University (No. I-00046), in accordance with the “Guide-
lines for proper conduct of animal experiments” proposed by the
Science Council of Japan; these guidelines conform to the standards
of the National Institutes of Health. All efforts were made to
minimize the suffering of the animals and the number of animals
needed to obtain reliable results. In all, 93 eight-week-old male
Wistar rats (Japan SLC Inc., Hamamatsu, Japan) weighing
200e250 g were used in the experiments. The rats were housed in
pairs in cages, in an air-conditioned room at 22e24 C under a
constant dayenight rhythm (14/10 h lightedark cycle, lights on at
05:00) for more than 2 weeks. They had ad libitum access to food
(laboratory chow, CE-2; Clea Japan, Hamamatsu, Japan) and water.
Upon reaching a body weight of 310e360 g, the rats were subjected
to the following experiments.
2.2. Intracerebroventricular administration of NA
In the morning (10:30e11:30), rats were placed in a stereotaxic
apparatus (Narishige, Tokyo, Japan) under urethane anesthesia
(1.0 g/kg, i.p.), as described previously in a published work of this
laboratory (14). The skull was drilled for intracerebroventricular
administration of NA using a stainless-steel cannula (outer diam-
eter of 0.3 mm). The stereotaxic coordinates of the tip of the can-
nula were as follows (in mm): AP 0.8, L 1.5, V 4.0 (AP, anterior
from the bregma; L, lateral from the midline; V, below the surface
of the brain), according to the rat brain atlas (15). The steel cannula
was injected into the left lateral ventricle 3 h before NA adminis-
tration as described below, and was retained until the end of the
experiment.
2.3. Drug administration
NA and naftopidil were dissolved in 10 mM phosphate-buffered
saline (PBS) containing 0.1% ascorbic acid (pH 7.4) and 10% N,N-
dimethylformamide (DMF), respectively. NA (3 or 30 mg/kg) was
slowly administered into the left lateral ventricle in a volume of
10 mL/animal using a cannula connected to a 10-mL Hamilton sy-
ringe (Hamilton, Reno, NV, USA) at a rate of 10 mL/min. Naftopidil
(10 or 30 mg/kg) was administered intraperitoneally in a volume of
1.0 mL/animal. Subsequently, NA was slowly administered as
described above, 3 h following the application of naftopidil. The
doses of naftopidil were determined according to previous reports
from our and other laboratories that had used similar doses of
naftopidil in rats (4,11,16). Furthermore, we have checked the dose-
dependent efﬁcacy of naftopidil in our preliminary study. The exact
location of the cannula injected in the brain was conﬁrmed at the
end of each experiment by verifying that cresyl violet, injectedthrough the cannula, had spread throughout the ventricular sys-
tem, as described previously (17). For voiding behavior studies, rats
were administered naftopidil intraperitoneally at 10:00 am once a
day, for two days.
2.4. Measurement of plasma AVP levels
A total of 70 rats placed in a stereotaxic apparatus were
randomly divided into ten groups in order to measure their plasma
AVP levels: NA administered groups at 3 and 30 mg/kg per animal,
i.c.v. (n ¼ 7 and 8, respectively); vehicle-1 (10 mL PBS-containing
0.1% ascorbic acid per animal, i.c.v.) administered group (n ¼ 7);
naftopidil administered groups at 10 and 30mg/kg, i.p. (n¼ 8 and 7,
respectively); vehicle-2 (1.0 mL10% DMF, i.p.) administered group
(n ¼ 6); 10 mg/kg naftopidil (i.p.) and NA (30 mg/kg, i.c.v.) admin-
istered group (n ¼ 8); 30 mg/kg naftopidil (i.p.) and NA (30 mg/kg,
i.c.v.) administered group (n¼ 6); vehicle-2 and NA (30 mg/kg, i.c.v.)
administered group (n ¼ 7); and vehicle-2 and vehicle-1 adminis-
tered group (n ¼ 6).
Blood samples (5 mL) were collected from the inferior vena cava
1 h after NA or vehicle administration into the left ventricle. All
blood samples were collected at 4:00 pm as described previously
(18), and were mixed with 1 mg/mL EDTA before centrifuged at
1600  g for 15 min at 4 C to obtain the plasma. The obtained
plasma samples were mixed with a protease inhibitor cocktail
(0.5 mL/mL plasma), and were kept at 80 C. These samples were
concentrated to 400 mL using a centrifugal concentrator, before AVP
levels were measured in duplicate using an ELISA kit (#ab133028;
Abcam, Cambridge, UK). The sensitivity of this assay (lower limit of
detection) was less than 3.39 pg/mL, and the intra-assay precision
was less than 5.9%.
2.5. Voiding behavior studies
Rats were randomly divided into two groups for examination of
voiding behaviors: naftopidil (30 mg/kg, i.p.) administered group
(n¼ 5) and vehicle-2 administered group (n ¼ 5). Voiding behavior
studies were performed according to methods described in our
previous reports (11). The rats received food and water ad libitum
from the time theywere initially placed inmetabolic cages. The rats
were kept for 24 h for adaptation, and recorded for the next 24 h.
Micturition frequency and total urine output were evaluated from
these recordings.
2.6. Urine production and osmolality
Fourteen rats were divided into the following groups: NA (30 mg/
kg, i.c.v.) administered group (n ¼ 5); NA (30 mg/kg, i.c.v.) and
naftopidil (30 mg/kg, i.p.) administered group (n ¼ 5); and vehicle-
1 and vehicle-2 administered group (n¼ 4). Before the experiment,
rats were catheterized at the bladder dome with a 22G needle for
urine collection, and a stainless cannula was inserted into the left
lateral ventricle for administration of NA as described above. The
catheterized bladder in the rat was emptied and the urethra was
clamped to prevent urine leakage. Vehicle-1 or NA (30 mg/kg, i.c.v.)
was centrally administered 3 h after intraperitoneal pretreatment
with vehicle-2 or naftopidil (30 mg/kg). Urine was collected 1 and
3 h after NA administration (at 4:00 pm and 6:00 pm, respectively).
We also determined urine osmolality for the following groups:
NA (30 mg/kg, i.c.v.) administered group (n ¼ 5); NA (30 mg/kg, i.c.v.)
and naftopidil (30 mg/kg, i.p.) administered group (n ¼ 5); and
vehicle-1 and vehicle-2 administered group (n ¼ 5). Urine was
collected 1 and 3 h after NA administration (at 4:00 pmand 6:00 pm,
respectively), and was centrifuged at 1600  g for 15 min at 4 C to
remove impurities. The urine osmolality (mOsmolality/kg H2O) of
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Fig. 2. Effect of naftopidil on plasma level of AVP. Blood samples were obtained from
the inferior vena cava 4 h after treatment with vehicle or naftopidil (10 or 30 mg/kg,
i.p.). Naf: naftopidil. Results are presented as mean ± SEM.
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2030; Aryray, Kyoto, Japan) based on the freezing point method (19).
2.7. Statistical analysis
Data are expressed as mean ± SEM. Comparisons between two
or more groups were performed by unpaired t-test or analysis of
variance (ANOVA) followed by Bonferroni post hoc test, respec-
tively. Differences with a p-value of 0.05 or less are considered
statistically signiﬁcant.
2.8. Drug and chemicals
Urethane, NA, and protease inhibitor cocktail were purchased
from Sigma Aldrich (St Louis, MO, USA). Naftopidil was purchased
from Tokyo Chemical Industry (Tokyo, Japan). All other chemicals
were from Nacalai Tesque (Kyoto, Japan), except stated otherwise.
3. Results
3.1. Effect of centrally administered NA on plasma level of AVP
We ﬁrst investigated whether centrally administered NA affects
plasma levels of AVP. It has been reported that AVP levels in plasma
and in the brain exhibit marked changes during light- and dark-
cycles (20). Furthermore, Greeley et al. (18) revealed that
maximum plasma AVP levels (approximately 13e18 pg/mL) were
observed during the midafternoon through the early evening in
rats. As shown in Fig. 1, treatment with vehicle-1 had no effect on
the basal plasma levels of AVP (19.2 ± 4.0 pg/mL), which were
consistent with the observations of Greeley et al. (18) and other
laboratories (21,22). On the other hand, NA (3 and 30 mg/kg/animal,
i.c.v.) dose-dependently decreased plasma AVP levels 1 h after its
administration (Fig. 1).
3.2. Effect of systemically administered naftopidil on plasma level of
AVP
To evaluate whether naftopidil by itself affects the plasma level
of AVP, rats received i.p. injections of naftopidil. As shown in Fig. 2,
there were no signiﬁcant differences in plasma AVP level between
rats 4 h after treatment with vehicle-2 or naftopidil.
3.3. Effect of systemically administered naftopidil on the centrally
administered NA-induced decrease in plasma level of AVP
Next, we investigatedwhether naftopidil affects the NA-induced
reduction in plasma AVP level. Rats were pretreated with vehicle-2
or naftopidil (10 and 30 mg/kg, i.p.) 3 h before NA administration
(30 mg/kg, i.c.v.). Administration of naftopidil at a higher dose0
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Fig. 1. Effect of centrally administered NA on plasma level of AVP. Blood samples were
obtained from the inferior vena cava 1 h after treatment with vehicle or NA (3 or 30 mg/
kg, i.c.v.). Results are presented as mean ± SEM. *p < 0.05 vs. control rats treated with
vehicle.effectively abolished the NA-induced decrease in plasma AVP level
(Fig. 3).
3.4. Voiding behaviors in rats systemically administered with
naftopidil
Results of the voiding behavior studies are shown in Table 1.
Basal levels of urine volume in rats treated with vehicle-2, collected
during light- and dark-cycles, were 8.4 ± 0.5 and 12.6 ± 2.2 mL,
respectively. Treatment with 30 mg/kg naftopidil (i.p.) produced no
signiﬁcant difference in urine volume between rats administered
with naftopidil (9.8 ± 1.0mL during light-cycle,12.1 ± 1.5mL during
dark-cycle) and vehicle-2, regardless of the light- and dark-cycle.
Similarly, basal levels of urinary frequency in the vehicle-treated
rats (7.0 ± 0.9 and 11.5 ± 1.2 times during light- and dark-cycles,
respectively) were not signiﬁcantly affected by naftopidil treat-
ment (5.4 ± 0.2 times during light-cycle, 8.6 ± 1.6 times during
dark-cycle).
3.5. Effect of systemically administered naftopidil on urine
production and osmolality in rats centrally administered with NA
To investigate whether naftopidil affects urine production and
its osmolality in rats treated with NA, urine was collected at 1 and
3 h after NA administration (30 mg/kg, i.c.v.; Table 2). Compared to
the vehicle-1 and -2 treated control group, NA administration
resulted in a signiﬁcant increase in urine volume that remained for
at least 3 h after its administration. Remarkably, the increase in
urine volume 3 h after NA administration was almost completely
suppressed when rats were pretreated with naftopidil (30 mg/kg,
i.p.) 3 h before NA administration. In contrast, there were no0
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Fig. 3. Effect of naftopidil on the NA-induced decrease in plasma level of AVP. Rats
were treated with vehicle or NA (30 mg/kg, i.c.v.) 3 h after pretreatment with vehicle or
naftopidil (10 or 30 mg/kg, i.p.). Blood samples were obtained from the inferior vena
cava 1 h after NA administration. Results are presented as mean ± SEM. *p < 0.05 vs.
control rats treated with vehicle. Naf: naftopidil. #p < 0.05 vs. NA-treated rats, pre-
treated with vehicle or 10 mg/kg naftopidil.
Table 1
Voiding behavior during light-cycle, dark-cycle, and the whole-day.
Urinary volume (mL) Micturition frequency (times)
Light-cycle Dark-cycle Whole-cycle Light-cycle Dark-cycle Whole-cycle
Vehicle 8.4 ± 0.5 12.6 ± 2.2 21.1 ± 1.9 7.0 ± 0.9 11.5 ± 1.2 18.5 ± 1.8
Naf 9.8 ± 1.0 12.1 ± 1.5 21.9 ± 2.4 5.4 ± 0.2 8.6 ± 1.6 14.0 ± 1.9
p-value 0.242 0.844 0.800 0.101 0.214 0.135
Vehicle: Wistar rats treated with 10% DMF (i.c.v.).
Naf: Wistar rats treated with naftopidil (30 mg/kg, i.p.).
p-Value: Vehicle-administered group vs. naftopidil-administered group.
Data are shown as mean ± SEM.
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administration between rats untreated and pretreated with nafto-
pidil. Urine osmolality decreased signiﬁcantly 1 h after NA treat-
ment compared to control rats. However, there were no signiﬁcant
differences in urine osmolality collected 3 h after NA treatment.
Although the decrease in urine osmolality was suppressed by naf-
topidil pre-administration, it was not statistically signiﬁcant.
4. Discussion
In this study, we demonstrated that 1) centrally administered
NA signiﬁcantly decreased plasma level of AVP in a dose-dependent
manner; 2) a decrease in plasma AVP level in rats induced by NA
was dose-dependently suppressed by pre-administration of naf-
topidil; and 3) while naftopidil suppressed NA-induced urine pro-
duction in rats, it had no effect on the urine production in normal
condition. These ﬁndings suggest a novel mechanism by which
naftopidil ameliorates nocturnal polyuria.
a1-Adrenoceptor antagonists are the most common drugs
used in the treatment of male LUTS suggestive of BPH, which act
via the relaxation of prostatic smooth muscles. Tamsulosin, an a1-
adrenoceptor antagonist, improves the maximum urinary ﬂow
rate and the frequency of nocturia, without decreasing nocturnal
urine volume in BPH patients (23). Similarly, terazosin, another
such an antagonist, also reduces the frequency of nocturia in BPH
patients despite there being no detectable reduction in nocturnal
urine volume (24). In limited countries including Japan, China,
and South Korea, naftopidil was administratively approved for the
treatment of BPH and BPH-associated LUTS (25). A clinical study
comparing tamsulosin and naftopidil by Nishino and colleagues
(26) demonstrated that while both drugs had similar efﬁcacy
against BPH/LUTS, naftopidil was more effective against nocturia
than tamsulosin. Furthermore, naftopidil has been reported to
decrease urine production and the frequency of voids at night-
time, regardless of incidences of sleep disturbance (3). Recently,Table 2
Inhibition of NA-induced decrease in urine production by naftopidil.
Urinary volume (mL)
1 h 3 h
Vehicle 0.5 ± 0.0 0.8 ± 0.0
NA 0.9 ± 0.1* 1.5 ± 0.2*
Naf + NA 0.7 ± 0.1 0.7 ± 0.0 #
Vehicle: Wistar rats treated with DMF (i.c.v.) 3 h after pretreatment with PBS (i.p.).
NA: Wistar rats treated with NA (30 mg/kg, i.c.v.) 3 h after pretreatment with PBS (i.p.).
Naf + NA: Wistar rats treated with NA (30 mg/kg, i.c.v.) 3 h after pretreatment with nafto
1 h: the volume of urine that was collected 1 h after NA treatment (4:00 pm).
3 h: the volume of urine that was collected 3 h after NA treatment (6:00 pm).
Total: the total volume of urine that was collected 1 and 3 h after NA treatment.
Data are shown as mean ± SEM.
*Signiﬁcantly different from the Vehicle group (p < 0.05).
#Signiﬁcantly differently from the NA group (p < 0.05).we revealed that naftopidil decreases micturition frequency and
urine production during the light-cycle in a rat model of
hypertension-related bladder dysfunction (11). It seemed that
naftopidil either directly or indirectly increased the secretion of
AVP in rats, thus contributing to the inhibition of urine produc-
tion during sleep. In the current study, we showed that naftopidil
suppressed the increase in urine production in rats centrally
administered with NA, but did not affect urine production in rats
untreated with NA, during both light- and dark-cycles. Recently,
naftopidil has been reported to be able to cross the bloodebrain
barrier and act on several regions in the central nervous system
as well as the bladder (4,27,28). Therefore, the effects of naftopidil
on urine production may be attributed to a direct inhibition of
dysregulated NA activity in the central nervous system, while, in
this study, we did not examine whether central administration of
other a1-adrenoceptor antagonists such as tamsulosin and ter-
azosin suppresses the NA-induced increase in urine production in
rats.
NA is an important neurotransmitter in the supraoptic nucleus,
and noradrenergic projection from the locus coeruleus is known to
promote wakefulness in the hypothalamus (29). In a recent study
involving a rat model of sleep disturbance induced by repeated
administration of corticosterone, NA level was found to be mark-
edly increased in the locus coeruleus and hypothalamus (30). On
the other hand, improvement in sleep disturbance has been re-
ported to decrease the frequency of nocturia, accompanied by
reduction in nocturnal polyuria in the elderly (31). Thus, we
considered the NA-induced increase in urine production in our
study as a model of nocturnal polyuria. This was supported by our
ﬁndings that systemic injection of naftopidil suppressed the in-
crease in urine production. However, little is known about the
relationship between noradrenergic neuronal activation in the
central nervous system and nocturnal polyuria. Therefore, further
studies are required to determine whether the former contributes
to the latter.Urinary osmolality (mOsmolality/kgH2O)
Total 1 h 3 h
1.3 ± 0.1 1965.4 ± 156.2 1964.5 ± 240.4
2.5 ± 0.2* 1498.0 ± 97.4* 1719.7 ± 159.6
1.4 ± 0.0 # 1748.2 ± 145.9 1941.0 ± 77.3
pidil (30 mg/kg, i.p.).
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of naftopidil on urine production in both basic and clinical studies
(3,11). While there is no information available that demonstrates
the mechanisms by which naftopidil directly reduces urine pro-
duction, it has been reported that naftopidil improves bladder ca-
pacity by suppressing C-ﬁber afferent activity (32). In the present
study, we found that naftopidil suppressed the decrease in plasma
AVP level in rats centrally administered NA. There are several re-
ports demonstrating that injection of NA into the cerebral ventri-
cles excites AVP-containing cells and stimulates release of AVP
(5,33); nonetheless, NA has also been reported to inhibit AVP
release (16,34). In general, activation of a1-adrenoceptor excites
neurons in the supraoptic nucleus and stimulates AVP release,
while b-adrenoceptor activation inhibits these neurons (35). It has
been suggested that the inhibitory effect of NA on AVP release may
be mediated by a2-adrenoceptors, as the infusion of clonidine, an
a2-adrenoceptor agonist, into the lateral cerebral ventricle mark-
edly decreased the release of AVP in anesthetized dogs (36). Since
these effects of the different adrenoceptor subtypes on AVP secre-
tion are not consistent with the antagonistic speciﬁcity of nafto-
pidil, it is necessary to clarify which subtype of adrenoceptor is
involved in the action of naftopidil in future investigations. To our
knowledge, this is the ﬁrst report demonstrating that the beneﬁcial
effect of naftopidil against NA-induced polyuria may be mediated
by its ameliorating action on NA-induced dysregulation in AVP
secretion from vasopressin-containing neurons into peripheral
blood. Furthermore, we found that central administration of NA
resulted in a signiﬁcant reduction in urine osmolality. These results
suggested that the observed changes in urine volume were
dependent on the renal action of AVP.
In the present study, we utilized rats that have been acclimated
for two weeks on a 14/10-h lightedark cycle according to the
breeding condition proposed by our Institute for Animal Research,
while other researchers have adopted a 12/12-h lightedark cycle to
investigate plasma AVP level in rats (37,38). Since the rhythm of
AVP secretion is maintained under dark conditions (39), we cannot
rule out the possibility that our particular lightedark cycle affected
the circadian change of plasma AVP level. Therefore, further in-
vestigations are necessary to clarify the mechanism by which naf-
topidil inhibits the reduction in plasma AVP level in rats centrally
administered with NA.5. Conclusions
In summary, systemic pre-administration of naftopidil sup-
pressed the decrease in plasma AVP level and the increase in urine
production in rats centrally administered with NA. However, naf-
topidil by itself had no effect on either parameter. These ﬁndings
can contribute towards explaining the mechanism by which naf-
topidil ameliorates nocturnal polyuria.Conﬂicts of interest
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